Legend Biotech Corp ADR(LEGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:09 PM ET (Korea 10/27 05:09)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 4.6% | Shs Outstand | 193.8M | Perf Week | 9.33% |
| Market Cap | 3.95B | Forward P/E | 37.66 | EPS next Y | 1357.95% | Insider Trans | -0.5% | Shs Float | 184.8M | Perf Month | 6.7% |
| Enterprise Value | 3.26B | PEG | - | EPS next Q | 0 | Inst Own | 51.06% | Short Float | 8.87% | Perf Quarter | 7.09% |
| Income | -0.09B | P/S | 3.1 | EPS this Y | 94.69% | Inst Trans | 1.77% | Short Ratio | 7.13 | Perf Half Y | -13.78% |
| Sales | 1.27B | P/B | 3.21 | EPS next 5Y | - | ROA | -5.34% | Short Interest | 16.39M | Perf YTD | -6.21% |
| Book/sh | 6.35 | P/C | 4.1 | EPS past 3/5Y | 16.8% 6.49% | ROE | -8.11% | 52W High | -45.63% ($37.50) | Perf Year | -36% |
| Cash/sh | 4.98 | P/FCF | - | Sales past 3/5Y | 106.67% 68.87% | ROIC | -6.86% | 52W Low | 25.55% ($16.24) | Perf 3Y | -68.27% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 71.96% | Gross Margin | 53% | Volatility(W/M) | 3.83% 4.69% | Perf 5Y | -60.99% |
| Dividend TTM | - | EV/Sales | 2.56 | Sales Y/Y TTM | 59.59% | Oper. Margin | -4.12% | ATR (14) | 0.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.94 | EPS Q/Q | 125.11% | Profit Margin | -7.21% | RSI (14) | 59.23 | Recom | 1.71 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | Sales Q/Q | 51.64% | SMA20 | 7.77% ($18.92) | Beta | 0.57 | Target Price | $45.21 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/8/11 | SMA50 | 4.45% ($19.52) | Rel Volume | 1.03 | Prev Close | $19.27 |
| Employees | 2900 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 59.86% 8.86% | SMA200 | -7.98% ($22.16) | Avg Volume(3M) | 2.30M | Price | $20.39 |
| IPO | 2020/6/5 | Option/Short | Yes/Yes | Trades | 13365 | Volume | 2,369,674 | Change | 5.81% |
🧬 This is an ADR (American Depositary Receipt) for a biotech company that develops and commercializes cell therapies. The company sells a cell therapy for a blood cancer (multiple myeloma) in partnership with a major pharmaceutical company and is rapidly growing its revenue, while also developing additional cell therapy pipelines — making it a healthcare stock. Its value is driven by sales of its key product and the expansion of its manufacturing capacity.
Over the past 1 year, on the lower side
46% below its 1-year high.
Traded about as much as usual. That is 103% of its average volume.
LEGN has a sound balance sheet but weak earning power
Of every $100 in sales, $4.12 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +94.7% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $310. Peers typically go for $1,575.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -61.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 51.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #60 of 594 in the industry
Based on market cap of $4B.
ARQT#58 Arcutis Biotherapeutics Inc $4B PER 153.6 
RLAY#59 Relay Therapeutics Inc $4B PER - LEGN#60 Legend Biotech Corp ADR $4B PER - 
ABCL#61 AbCellera Biologics Inc $4B PER - 
TNGX#62 Tango Therapeutics Inc $4B PER - 
FAQ
What kind of company is LEGN?
LEGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LEGN?
The market cap of LEGN is approximately $4.0B, ranking 1,531 within its sector.
What is the 52-week high and low for LEGN?
LEGN has recorded a 52-week high of $37.50 and a low of $16.24.
